

APAC Biotech, Diakonos to bring new immunotherapy technology to India

26 June 2018 | News

This new technology effectively targets and activates the tumor antigen-specific CTL-response



India-Based APAC Biotech and US-Based Diakon Research sign a first-of-its-kind technology transfer and licensing agreement to bring new immunotherapy technology to India as an advancement of immuno-oncology therapeutics for solid tumors.

This new path breaking technology effectively targets and activates the tumor antigen specific CTL-response and is differentiated from peer technologies in its ability to generate durable immunological memory.

On the basis of pre-clinical animal data shared by Dr. William Decker and his research team at Baylor College of Medicine, APAC Biotech plans to launch phase II clinical trials in India for advanced brain and pancreatic cancers that have limited treatment options.

"We are committed to accelerating the availability of novel immuno-oncology treatments to patients with high unmet medical needs in India and around the globe," said Mr. Arun K. Mehra, CEO, APAC Biotech Pvt. Ltd, the new long-term memory potentiation technology is a highly promising, best-in-class cancer immunotherapy anticipated to improve outcomes even further.

APAC management is in talks with large investors for production scale-up of currently approved products and future clinical development trials.